Peptide Companion
Back to catalog
Peptide Companion
single
Weight Management
Vial: 10 mg

Cagrilintide (10 mg Vial)

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile.

Detailed protocol below.

Dosing Schedule
Week/PhaseWeekly Dose (mg)Units (per injection)Volume (mL)
Weeks 1–20.6 mg18 units0.18 mL
Weeks 3–41.2 mg36 units0.36 mL
Weeks 5–62.4 mg72 units0.72 mL
Weeks 7–16 (Maintenance)4.5 mg135 units1.35 mL
Supplies Needed
  • •Peptide Vials (Cagrilintide, 10 mg each):
  • •Syringes:
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each week.
References

  • The Lancet (2021)

    Once‑weekly cagrilintide for weight management: phase 2 dose‑finding trial (Lau et al.)

    View source

  • Int J Mol Sci (2024)

    Amylin, another important neuroendocrine hormone for treatment of diabesity

    View source

  • PMC (2022)

    Mediators of amylin action in metabolic control

    View source

  • The Lancet (2021)

    Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks

    View source

  • N Engl J Med (2025)

    REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity

    View source

  • The Lancet (2021)

    Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.)

    View source

  • J Med Chem (2021)

    Development of cagrilintide: a long‑acting amylin analogue

    View source

  • Brain Res Rev (2005)

    Pancreatic amylin as a centrally acting satiating hormone

    View source

  • PMC (2006)

    Pancreatic signals controlling food intake: insulin, glucagon, and amylin

    View source

  • PMC (2016)

    Amylin‑mediated control of glycemia, energy balance, and cognition

    View source

  • PMC (2024)

    Clinical pharmacokinetics of semaglutide: systematic review (includes cagrilintide PK data)

    View source

  • N Engl J Med (2025)

    REDEFINE 2: Cagrilintide–semaglutide in adults with overweight/obesity and type 2 diabetes

    View source

  • CDC

    Vaccine administration: subcutaneous injection technique and site guidance

    View source

  • CDC (PDF)

    You Call the Shots: subcutaneous injection diagram and best practices

    View source

  • PMC (2019)

    Subcutaneous drug delivery: pharmacologic considerations and techniques

    View source

  • American College of Cardiology (2025)

    REDEFINE 1 and REDEFINE 2 journal scan summary

    View source

  • The Lancet (2023)

    Efficacy and safety of CagriSema in type 2 diabetes: phase 2 trial (Frias et al.)

    View source

  • PMC (2024)

    Efficacy and safety of cagrilintide and CagriSema: systematic review and meta‑analysis

    View source

Educational content adapted from peptidedosages.com. Not medical advice.